ONCE-MONTHLY ORAL IBANDRONATE TREATMENT IN AN ADOLESCENT WITH RECURRENT FRACTURES AND INADEQUATELY LOW BONE MASS
نویسندگان
چکیده
منابع مشابه
Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
CONTEXT Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (Q...
متن کاملIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
Osteoporosis is a major healthcare problem that continues growing as the population ages. Sufferers become increasingly susceptible to fractures, which compromise physical and emotional health and increase healthcare costs. Bisphosphonates are the most widely used medicines for the treatment and prevention of postmenopausal osteoporosis. However, therapeutic adherence is suboptimal, meaning tha...
متن کاملEfficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density--ESTHER study.
INTRODUCTION Osteoporosis usually affects post-menopausal women. Treatment is individualized and requires an approach that will provide long-term compliance to prevent fractures. Studies conducted so far suggest inadequate compliance and persistence in weekly bisphosphonate treatment (under 43% after a year of treatment). Ibandronate, as a powerful bisphosphonate, has made it possible for the f...
متن کاملTreatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*
Osteoporosis is a common and debilitating condition associated with significant morbidity and mortality. The efficacy and safety of oral bisphosphonates for the treatment of osteoporosis are well established. However, patient adherence and persistence on treatment are suboptimal. This randomised open-label multi-centre study of 6-months' duration compared persistence on treatment in postmenopau...
متن کاملPatient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
OBJECTIVE CURRENT, a large, open-label, 6-month, multicenter study, was designed to assess patient satisfaction levels and patient treatment preference after switching from weekly oral bisphosphonates to monthly oral ibandronate for a period of 6 months. METHODS This study enrolled postmenopausal women who had taken a weekly oral bisphosphonate for at least 3 months for prevention or treatmen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Paediatrics and Child Health
سال: 2012
ISSN: 1034-4810
DOI: 10.1111/j.1440-1754.2012.02498.x